These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31804219)

  • 1. [MOLECULAR GENETIC ASPECTS OF THE DEVELOPMENT OF THE MUCOPOLYSACCHARIDOSES (REVIEW)].
    Zharmakhanova G; Syrlybayeva L; Nurbaulina E; Batyrova T; Baikadamova L
    Georgian Med News; 2019 Oct; (295):152-159. PubMed ID: 31804219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of Mucopolysaccharidoses, an Update.
    Fecarotta S; Tarallo A; Damiano C; Minopoli N; Parenti G
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underestimated Aspect of Mucopolysaccharidosis Pathogenesis: Global Changes in Cellular Processes Revealed by Transcriptomic Studies.
    Gaffke L; Pierzynowska K; Podlacha M; Hoinkis D; Rintz E; Brokowska J; Cyske Z; Wegrzyn G
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic aspects of mucopolysaccharidoses].
    Lacombe D; Germain DP
    Arch Pediatr; 2014 Jun; 21 Suppl 1():S22-6. PubMed ID: 25063380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
    Lau AA; Hemsley KM
    J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mucopolysaccharidoses].
    Fukuda S; Sukegawa K; Tomatsu S; Orii T
    Nihon Rinsho; 1995 Dec; 53(12):3019-24. PubMed ID: 8577052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses.
    Shapiro EG; Escolar ML; Delaney KA; Mitchell JJ
    Mol Genet Metab; 2017 Dec; 122S():8-16. PubMed ID: 29128371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mucopolysaccharidoses: a success of molecular medicine.
    Clarke LA
    Expert Rev Mol Med; 2008 Jan; 10():e1. PubMed ID: 18201392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Locus differentiation of hereditary mucopolysaccharidoses].
    Odinokova ON; Lebedeva TV; Krasnopol'skaia KD; Freĭdin MI
    Vopr Med Khim; 1986; 32(2):45-9. PubMed ID: 3085344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.
    Pan D
    Curr Pharm Biotechnol; 2011 Jun; 12(6):884-96. PubMed ID: 21235445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
    Shapiro EG; Jones SA; Escolar ML
    Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
    Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
    Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatments for the mucopolysaccharidoses: from pathophysiology to therapy.
    Fecarotta S; Gasperini S; Parenti G
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):124. PubMed ID: 30442204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
    Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for Mucopolysaccharidoses.
    Sawamoto K; Chen HH; Alméciga-Díaz CJ; Mason RW; Tomatsu S
    Mol Genet Metab; 2018 Feb; 123(2):59-68. PubMed ID: 29295764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation in VPS33A affects metabolism of glycosaminoglycans: a new type of mucopolysaccharidosis with severe systemic symptoms.
    Kondo H; Maksimova N; Otomo T; Kato H; Imai A; Asano Y; Kobayashi K; Nojima S; Nakaya A; Hamada Y; Irahara K; Gurinova E; Sukhomyasova A; Nogovicina A; Savvina M; Yoshimori T; Ozono K; Sakai N
    Hum Mol Genet; 2017 Jan; 26(1):173-183. PubMed ID: 28013294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS.
    Byers S; Rozaklis T; Brumfield LK; Ranieri E; Hopwood JJ
    Mol Genet Metab; 1998 Dec; 65(4):282-90. PubMed ID: 9889015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of brain disease in the mucopolysaccharidoses.
    Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
    Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnology applied to treatment of mucopolysaccharidoses.
    Schuh RS; Baldo G; Teixeira HF
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1709-1718. PubMed ID: 27322551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses.
    Rapoport DM; Mitchell JJ
    Mol Genet Metab; 2017 Dec; 122S():49-54. PubMed ID: 28964643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.